Product Images Irinotecan Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 4 images provide visual information about the product associated with Irinotecan Hydrochloride NDC 45963-614 by Actavis Pharma, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
9a178e71-figure-01 - irinotecan hcl injection premier 078589 1
9a178e71-figure-02 - irinotecan hcl injection premier 078589 2
9a178e71-figure-03 - irinotecan hcl injection premier 078589 3
This is a medical document presenting the results of a study involving Irinotecan and 5-FU treatments. The data includes the number of patients (127 and 129), the median time of follow-up (15 months), and median values (108 and 85 months) for two different factors. There is a probability statistic of 0.044 and a p-value of 0.035 obtained from a log-rank test.*
1 - irinotecan hcl injection premier 078589 4
Irinotecan Hydrochloride Injection is a prescription medicine used for treating cancer. It should be diluted and given through intravenous use only. It is a cytotoxic agent that comes in a single-dose vial. The dosage and administration should be followed as directed in the package insert. The vial stopper is not made with natural rubber latex, and it is sterile, nonpyrogenic, and preservative-free. The usual dosage and other details about storage and recommended usage are given in the insert. PREMIERProRx is a registered trademark used under license.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.